This post was originally published on this site Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were presented at the American Urological Association’s 2019 Annual Meeting, May 3-6, in Chicago, in the study, “Survival…
This post was originally published on this site Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called My Mentor Connections, the program enlists caregivers and patients as mentors who volunteer to provide answers and support over the phone to other patients or…
This post was originally published on this site With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS)…
This post was originally published on this site Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial shows. Trastuzumab deruxtecan is a combination of the anti-cancer HER2-targeting antibody trastuzumab (marketed under the brand name Herceptin), and an…
This post was originally published on this site Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. This approval — which makes the regimen accessible to physicians and eligible patients in Canada — was…
This post was originally published on this site The California Institute for Regenerative Medicine (CIRM) has awarded a $4.6 million grant to researchers at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research for an ongoing Phase 1 clinical trial testing a new immunotherapy for advanced sarcoma and other hard-to-treat cancers.…
This post was originally published on this site I remember when my daughter performed at a talent show at her school. I’d just had my fourth round of chemotherapy, and my condition was critical. For me, every chemo session had its own little life cycle, each with a unique set of challenges and logistics. Because…
This post was originally published on this site Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods of time — as a standard treatment for people with localized prostate cancer, a study shows. The study, “Stereotactic Body Radiotherapy for Localized Prostate Cancer: A…
This post was originally published on this site An analysis of circulating tumor DNA, or ctDNA, can help guide treatment decisions for patients with difficult-to-treat high-grade serous ovarian cancer, a study shows. The study, “Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer,” was published in journal Precision Oncology. Cancers generally develop due…
This post was originally published on this site A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed or refractory multiple myeloma. The study, ongoing in Taiwan, is being conducted by I-Mab Biopharma, which holds exclusive…
